These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19053784)

  • 41. Pharmacological characterization of human NPFF(1) and NPFF(2) receptors expressed in CHO cells by using NPY Y(1) receptor antagonists.
    Mollereau C; Mazarguil H; Marcus D; Quelven I; Kotani M; Lannoy V; Dumont Y; Quirion R; Detheux M; Parmentier M; Zajac JM
    Eur J Pharmacol; 2002 Sep; 451(3):245-56. PubMed ID: 12242085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors.
    Stewart M; Steinig AG; Ma C; Song JP; McKibben B; Castelhano AL; MacLennan SJ
    Biochem Pharmacol; 2004 Jul; 68(2):305-12. PubMed ID: 15194002
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [N-methyl-3H3]AZ10419369 binding to the 5-HT1B receptor: in vitro characterization and in vivo receptor occupancy.
    Maier DL; Sobotka-Briner C; Ding M; Powell ME; Jiang Q; Hill G; Heys JR; Elmore CS; Pierson ME; Mrzljak L
    J Pharmacol Exp Ther; 2009 Jul; 330(1):342-51. PubMed ID: 19401496
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor.
    Miranda LP; Holder JR; Shi L; Bennett B; Aral J; Gegg CV; Wright M; Walker K; Doellgast G; Rogers R; Li H; Valladares V; Salyers K; Johnson E; Wild K
    J Med Chem; 2008 Dec; 51(24):7889-97. PubMed ID: 19053766
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Self-regulation of agonist activity at the Y receptors.
    Parker SL; Parker MS; Sah R; Balasubramaniam A; Sallee FR
    Peptides; 2007 Feb; 28(2):203-13. PubMed ID: 17194507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis and evaluation of a series of 2,4-diaminopyridine derivatives as potential positron emission tomography tracers for neuropeptide Y Y1 receptors.
    Kameda M; Ando M; Nakama C; Kobayashi K; Kawamoto H; Ito S; Suzuki T; Tani T; Ozaki S; Tokita S; Sato N
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5124-7. PubMed ID: 19640706
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GPC receptors and not ligands decide the binding mode in neuropeptide Y multireceptor/multiligand system.
    Lindner D; van Dieck J; Merten N; Mörl K; Günther R; Hofmann HJ; Beck-Sickinger AG
    Biochemistry; 2008 Jun; 47(22):5905-14. PubMed ID: 18457425
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [3H]Org 43553, the first low-molecular-weight agonistic and allosteric radioligand for the human luteinizing hormone receptor.
    Heitman LH; Oosterom J; Bonger KM; Timmers CM; Wiegerinck PH; Ijzerman AP
    Mol Pharmacol; 2008 Feb; 73(2):518-24. PubMed ID: 17989351
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of substituted 2,4,4-triarylimidazoline derivatives as potent and selective neuropeptide Y Y5 receptor antagonists.
    Sato N; Jitsuoka M; Ishikawa S; Nagai K; Tsuge H; Ando M; Okamoto O; Iwaasa H; Gomori A; Ishihara A; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1670-4. PubMed ID: 19233647
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis and structure activity relationship of guanidines as NPY Y5 antagonists.
    Aquino CJ; Ramanjulu JM; Heyer D; Daniels AJ; Palazzo F; Dezube M
    Bioorg Med Chem; 2004 May; 12(10):2691-708. PubMed ID: 15110851
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuropeptide Y receptors in primary human brain tumors: overexpression in high-grade tumors.
    Körner M; Reubi JC
    J Neuropathol Exp Neurol; 2008 Aug; 67(8):741-9. PubMed ID: 18648328
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [3H]-MRE 2029-F20, a selective antagonist radioligand for the human A2B adenosine receptors.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Fruttarolo F; Romagnoli R; Moorman AR; Gessi S; Merighi S; Varani K; Borea PA
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3607-10. PubMed ID: 15177484
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Determination of affinity and activity of ligands at the human neuropeptide Y Y4 receptor by flow cytometry and aequorin luminescence.
    Ziemek R; Schneider E; Kraus A; Cabrele C; Beck-Sickinger AG; Bernhardt G; Buschauer A
    J Recept Signal Transduct Res; 2007; 27(4):217-33. PubMed ID: 17885919
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Examining the binding properties of MK-0974: a CGRP receptor antagonist for the acute treatment of migraine.
    Moore EL; Burgey CS; Paone DV; Shaw AW; Tang YS; Kane SA; Salvatore CA
    Eur J Pharmacol; 2009 Jan; 602(2-3):250-4. PubMed ID: 19084002
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and binding studies of 2-O- and 11-O-substituted N-alkylnoraporphines.
    Si YG; Gardner MP; Tarazi FI; Baldessarini RJ; Neumeyer JL
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3971-3. PubMed ID: 18585036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Determination of neuropeptide Y Y1 receptor antagonist BIBP 3226 and evaluation of receptor expression based on liquid chromatography coupled with tandem mass spectrometry.
    Barreiros L; Silva EMP; Alencastre IS; Lamghari M; Segundo MA
    Anal Bioanal Chem; 2020 Sep; 412(24):6625-6632. PubMed ID: 32728863
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The novel neuropeptide Y Y5 receptor antagonist Lu AA33810 [N-[[trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl]methyl]-methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of stress sensitivity.
    Walker MW; Wolinsky TD; Jubian V; Chandrasena G; Zhong H; Huang X; Miller S; Hegde LG; Marsteller DA; Marzabadi MR; Papp M; Overstreet DH; Gerald CP; Craig DA
    J Pharmacol Exp Ther; 2009 Mar; 328(3):900-11. PubMed ID: 19098165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and SAR of substituted tetrahydrocarbazole derivatives as new NPY-1 antagonists.
    Di Fabio R; Giovannini R; Bertani B; Borriello M; Bozzoli A; Donati D; Falchi A; Ghirlanda D; Leslie CP; Pecunioso A; Rumboldt G; Spada S
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1749-52. PubMed ID: 16364642
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Involvement of neuropeptide Y Y(1) receptors in the acute, chronic and withdrawal effects of nicotine on feeding and body weight in rats.
    Nakhate KT; Dandekar MP; Kokare DM; Subhedar NK
    Eur J Pharmacol; 2009 May; 609(1-3):78-87. PubMed ID: 19285064
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of a selective and potent radioactive ligand for histamine H(3) receptors: A compound potentially useful for receptor occupancy studies.
    Mitobe Y; Ito S; Mizutani T; Nagase T; Sato N; Tokita S
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4075-8. PubMed ID: 19553110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.